Technology
Health
Biotechnology

InflaRx

$39.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.81 (-4.34%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell InflaRx and other stocks, options, ETFs, and crypto commission-free!

About

InflaRx N.V. Common Stock, also called InflaRx, is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Read More Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Employees
38,000
Headquarters
Jena, Thueringen
Founded
2007
Market Cap
1.03B
Price-Earnings Ratio
Dividend Yield
Average Volume
87.15K
High Today
$42.12
Low Today
$39.71
Open Price
$41.61
Volume
58.93K
52 Week High
$53.10
52 Week Low
$20.31

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2017 IPO
Europe (Non-UK)

Earnings

-$0.47
-$0.35
-$0.24
-$0.12
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 28, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.